Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Jennifer Viera - IR Jay Luly - President and CEO Paul Mellett - CFO Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Roy Buchanan - JMP Roanna Ruiz - Leerink Amy Li - Jefferies Eric Joseph - JPMorgan Operator Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal First Quarter Financial Results Conference Call. ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.90%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.11 per share when it actually produced a loss of $1.33, delivering a surprise of 36.97%.Over the last four quarters, th ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023. “In 2024, Enanta began a year which will be marked by execution and value creation across the company. We are preparing for multiple catalysts across our pipeline in 2024, starting with RSV, where we anticipate reporting topline data f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Title of each class | Trading Symbol(s) | Name of each exchange on which regis ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company’s business and re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial DELAWARE 2834 04-3205099 ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Conference Call November 20, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jay Olson - Oppenheimer Ed Arce - H.C. Wainwright & Company Eric Joseph - JPMorgan Liisa Bayko - Evercore Roy Buchanan - JMP Operator Good afternoon, and welcom ...

Pharmaceuticals Great Chemistry Cures COVID-19: Phase 2 (SPRINT) complete A Proven Approach to Drug Discovery Proven Track Record of Success Strong Balance Sheet 3 | --- | --- | --- | |-------|-------|-------------------------------------------------------------------------------------------------| | | | | | HCV | HBV | viral infections Several therapeutic areas with goal of building multiple approaches in each | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------|----------------|- ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Tara Kieffer - Senior Vice President of New Product Strategy and Development Conference Call Participants Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Ed Arce - H.C. Wainwright Eric Joseph - JPMorgan Roy Buchanan - JMP Securities Amy Li - Jefferies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3205099 (State or other jurisdiction of incorporation or organization) 5 ...